Analysts have been eager to weigh in on the Healthcare sector with new ratings on SAGE Therapeutics (SAGE – Research Report) and Palisade Bio (PALI – Research Report).
SAGE Therapeutics (SAGE)
In a report released today, Douglas Tsao from H.C. Wainwright maintained a Hold rating on SAGE Therapeutics, with a price target of $28.00. The company’s shares closed last Wednesday at $12.31.
According to TipRanks.com, Tsao is a 4-star analyst with an average return of
The word on The Street in general, suggests a Hold analyst consensus rating for SAGE Therapeutics with a $24.43 average price target, an 88.5% upside from current levels. In a report issued on April 4, RBC Capital also maintained a Hold rating on the stock with a $26.00 price target.
See the top stocks recommended by analysts >>
Palisade Bio (PALI)
In a report released yesterday, Naz Rahman from Maxim Group maintained a Buy rating on Palisade Bio, with a price target of $22.50. The company’s shares closed last Wednesday at $6.91, close to its 52-week low of $3.82.
According to TipRanks.com, Rahman is ranked 0 out of 5 stars with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Palisade Bio with a $22.50 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on SAGE:
- SAGE Therapeutics’ Promising Parkinson’s Treatment Results
- Sage Therapeutics management to meet with Piper Sandler
- SAGE Therapeutics Board Member Announces Retirement
- Sage Therapeutics price target raised to $29 from $24 at JPMorgan
- JPMorgan biotech analysts to hold an analyst/industry conference call
